Appendix B: Panel Roster and Financial Disclosures
Progressive Multifocal Leukoencephalopathy
| Member | Institution | Financial Disclosure | |
|---|---|---|---|
| Company | Relationship | ||
| Shruti Agnihotri | The University of Alabama at Birmingham Marnix E. Heersink School of Medicine | Moderna Pfizer Gilead Sciences Johnson & Johnson | Equity Interest |
| Paola Cinque | San Raffaele Scientific Institute, Milan, Italy | Pfizer Takeda Pharmaceuticals ShirePharma Polpharma | Data and Safety Monitoring Board |
Cellevolve Sobi | Advisory Board | ||
Excision BioTherapeutics Janssen | Consultant | ||
| David Clifford* | Washington University School of Medicine in St. Louis | Wave Life Sciences Atara Biotherapeutics Cellevolve Takeda Pharmaceuticals | Data and Safety Monitoring Board |
Arena Pharmaceuticals Roche Seagen (Seattle Genetics) | Consultant | ||
| National Institutes of Health | Research Support | ||
| Irene Cortese | National Institutes of Health | Nouscom PDC*line Pharma Life Sciences Partners V Cv | Equity Interest |
| Jose M. Miro | Hospital Clinic de Barcelona-IDIBAPS, University of Barcelona, Spain | None | N/A |
| C. Sabrina Tan | The University of Iowa Carver College of Medicine | Cellevolve | Advisory Board |
| * Section Group Lead Note: Members are required to update disclosures annually and to notify guideline staff of any relevant changes in status during the interim. | |||
Download Guidelines
- Section Only PDF (18.86 KB)
- Full Guideline PDF (6.09 MB)
- Tables Only PDF (1.13 MB)